Before revision: It is currently undergoing a Phase III clinical trial to determine efficacy and clinical usefulness.TK scientific results and regulatory path will be presented today at the 40° annual meeting of the European Society for Blood and Marrow Transplantation TK is currently being investigated in patients suffering from acute leukemia in first or subsequent complete remission and at high risk of relapse or in patients with relapsed disease who are candidates for haploidentical transplantation of hemopoietic stem cells (taken from a partially HLA-compatible family donor).
After revision: It is currently undergoing a Phase III clinical trial to determine efficacy and clinical usefulness.TK scientific results and regulatory path will be presented today at the 40° annual meeting of the European Society for Blood and Marrow Transplantation TK is currently being investigated in patients with acute leukemia in first or subsequent complete remission and at high risk of relapse or in patients with relapsed disease who are candidates for haploidentical transplantation of hemopoietic stem cells (taken from a partially HLA-compatible family donor).